GLENMARKPharmaceuticals
Glenmark Pharmaceuticals Ltd — PE Ratio & Valuation Analysis
₹2170.50
+0.82%
Current P/E21.78xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E49.5x56.0% below avg
✅
31.4% Discount to Industry
GLENMARK P/E 21.78x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹37.11 | ₹2035 | 54.8x |
| 2023 | ₹10.53 | ₹852 | 80.9x |
| 2022 | ₹33.37 | ₹425 | 12.7x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Glenmark Pharmaceuticals Ltd Valuation
Glenmark Pharmaceuticals Ltd (GLENMARK) currently trades at 21.78x earnings. The Pharmaceuticals sector average PE is 31.77x. GLENMARK is trading at a discount to peers — may indicate relative value. Historically, GLENMARK has traded at an average PE of 49.5x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
15.79%
Dividend Yield
0.13%
More on Glenmark Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.